TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31184796
Drug: Open-ended group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-ended group intervention based on a cognitive behavioural therapy for insomnia self-help book
Study: 31184796
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the book and the open-ended group intervention
Study: 18318773
Drug: Udenafil 50
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 50 mg
Study: 18162935
Drug: Killed oral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed oral cholera vaccine (mass immunization of older children and adults)
Study: 18162935
Drug: Vaccine coverage
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine coverage of adult women
Study: 7477166
Drug: Triiodothyronine (liothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine (liothyronine sodium) administered as an intravenous bolus of 0.8 microgram per kilogram of body weight and then as an infusion of 0.113 microgram per kilogram per hour for six hours
Study: 2401187
Drug: Lornoxicam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (4 mg as a film-coated tablet) alone
Study: 2401187
Drug: Maalox (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maalox (10 ml)
Study: 2401187
Drug: Solugastril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solugastril (10 g)
Study: 6381007
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) at 1.00 +/- 0.06 U insulin/h from 10 p.m. to 8 a.m.
Study: 6381007
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of insulin infusion between 11 p.m. and 1 a.m.
Study: 28857811
Drug: Urinary biomarker‐triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary biomarker‐triggered KDIGO care bundle (early optimization of fluid status, maintenance of perfusion pressure, discontinuation of nephrotoxic agents)
Study: 27788811
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (50 mg/kg) administered in the last 30 minutes of the operation.
Study: 20055981
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus paclitaxel (CP) - carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21
Study: 20055981
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus pegylated liposomal doxorubicin (CLD) - carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28
Study: 12566175
Drug: L-365,260 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260 30 mg
Study: 12566175
Drug: L-365,260 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260 120 mg
Study: 3907395
Drug: Enprofylline 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 1.5 mg/kg b.wt.
Study: 3907395
Drug: Theophylline 5
Normalized name: theophylline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 5 mg/kg b.wt.
Study: 30314913
Drug: two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: two doses of 9vHPV
Study: 27622956
Drug: Iontophoretic SM
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoretic SM injection
Study: 20051587
Drug: Tramadol Contramid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol Contramid OAD 200-mg tablets
Study: 20051587
Drug: tramadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol IR 50-mg tablets
Study: 18719632
Drug: CM3 (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM3 (six capsules taken 30 min before a standardized solid meal)
Study: 15813665
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate 50/100 microg twice daily
Study: 15813665
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 microg twice daily plus oral montelukast 10mg daily
Study: 8971297
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg topical pharyngeal lidocaine spray
Study: 8971297
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg topical pharyngeal lidocaine spray
Study: 28500254
Drug: Dabigatran (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (110 mg BID for normal renal function, 75 mg BID for impaired renal function)
Study: 21447137
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine
Study: 21447137
Drug: Lingual infiltration
Normalized name: Nitroglycerin Lingual Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingual infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine
Study: 21447137
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration
Study: 19004194
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at bilateral Hegu (LI 4) plus intravenous dripping of oxytocin
Study: 19004194
Drug: Intravenous dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dripping of oxytocin
Study: 10795744
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg QAM
Study: 10795744
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg QAM
Study: 10795744
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg QAM
Study: 1740204
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (GnRH agonist)
Study: 20137647
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy + surgical resection (CS group)
Study: 9531580
Drug: low-dose IFN-alpha2b
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose IFN-alpha2b (3 MIU, 5 days/week)
Study: 8554248
Drug: Vitamin D3,
Normalized name: Vitamin D3, 25 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3, 400 IU in one tablet daily
Study: 19370185
Drug: Nimulid (N)
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimulid (N) 100 mg 2 x/day for 20 days
Study: 19370185
Drug: Tenaprost (T)
Normalized name: beraprost
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenaprost (T) 100 mg 2 x/day for 20 days
Study: 16443872
Drug: Model Predictive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model Predictive Control (MPC) algorithm (n = 30, target range 80-110 mg/dl)
Study: 11780205
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (donors without G-CSF)
Study: 9663838
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m., clarithromycin 250 mg b.d. and amoxycillin 500 mg b.d. (OAC)
Study: 9663838
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m., metronidazole 400 mg b.d. and clarithromycin 250 mg b.d. (OMC)
Study: 2859781
Drug: Acebutolol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol with diuretic
Study: 2859781
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with diuretic
Study: 27085565
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C intervention (1,000 mg every other day)
Study: 24641937
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy (GFFC) + Enoxaparin (40 mg daily)
Study: 16037104
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist ganirelix daily (0.25 mg each, n = 37)
Study: 16037104
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist ganirelix every other day (0.25 mg each, n = 36)
Study: 12351376
Drug: Idarubicin 10
Normalized name: IDArubicin 10 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 10 mg/m(2) (group 2A)
Study: 12351376
Drug: Idarubicin 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 12 mg/m(2) (group 2B)
Study: 8847094
Drug: Ragweed allergen
Normalized name: ALLERGENIC EXTRACT, SHORT RAGWEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed allergen (RWA) treatment of sera
Study: 2187700
Drug: Almitrine 50
Normalized name: almitrine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 50 mg b.d. p.o.
Study: 30711416
Drug: CCZ (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCZ (75 mg twice daily)
Study: 30711416
Drug: CCZ+RBV (1000/1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCZ+RBV (1000/1200 mg daily)
Study: 19141125
Drug: Basiliximab (Simulect)
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab (Simulect) administration
Study: 19141125
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (recipients without basiliximab injection)
Study: 18184535
Drug: d‐MPH bimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH bimodal release formulation (20 mg)
Study: 18184535
Drug: d‐MPH immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH immediate release formulation (two 10 mg doses given 4 h apart)
Study: 18184535
Drug: d,l‐MPH bimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l‐MPH bimodal release formulation (40 mg)
Study: 7993707
Drug: Antiphospholipid antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibodies (aPL)
Study: 3251497
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of sustained release PPA
Study: 30698069
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (radiotherapy for endometrial cancer)
Study: 30698069
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (chemotherapy for ovarian cancer)
Study: 30698069
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy or early-stage disease
Study: 30698069
Drug: Clinical characteristics
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical characteristics (comorbidities, treatment, tumor stage)
Study: 26429700
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with dihydroartemisinin‐piperaquine
Study: 26429700
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment with dihydroartemisinin‐piperaquine
Study: 21199881
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine
Study: 21148051
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + AICAR (67 mg·kg(‐1))
Study: 21148051
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + placebo (saline)
Study: 16904415
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (20 microg of ethinylestradiol (EE)/100 microg of levonorgestrel)
Study: 16904415
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (15 microg of EE/60 microg of gestodene)
Study: 16904415
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (combined oral contraceptives and vaginal ring)
Study: 12829654
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (heart rate‐controlled endurance training twice a week and supervised muscle strength training twice a week for 12 months)
Study: 6116723
Drug: Gonococcal pilus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonococcal pilus vaccine
Study: 1701817
Drug: Preexisting antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preexisting antibodies
Study: 6514179
Drug: Diazepam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (8 mg)
Study: 31145207
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin (TI) 1 unit/drop 4 times per day for 4 weeks
Study: 31145207
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin (TI)
Study: 30522397
Drug: Homemade street
Normalized name: Welmedix Homecare Pro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homemade street foods (e.g., fried cakes, stewed meat/fish/liver dishes)
Study: 26436491
Drug: TORS plus
Normalized name: Lipo Factors Plus B
Approvals — FDA: no, EMA: no, PMDA: no
Description: TORS plus adjuvant therapy
Study: 25152982
Drug: 36 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36 weeks PEG‐RBV therapy (group B)
Study: 25152982
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks PEG‐RBV therapy (group A)
Study: 21112054
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 μg 3 hours before MVA
Study: 21112054
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 μg 3 hours before EVA
Study: 19158210
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation of 125 mg FeSO4 daily from 10 weeks to 9 months postpartum (IDA-Fe)
Study: 1130879
Drug: Intraluminal 5
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal 5 FU (30mg/kg) with intravenous 5 FU (10mg/kg) on the first two postoperative days and 5 subsequent postoperative courses of oral 5 FU (90 mg/kg in each 18 day course) over one year period.
Study: 26501118
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment (lansoprazole, clarithromycin, metronidazole)
Study: 23596810
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng extract (1500 mg)
Study: 18585631
Drug: Ofloxacin administration
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin administration after each BCG instillation
Study: 16864926
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (CAA) - verapamil
Study: 16864926
Drug: Beta-blocker (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (BB) - bisoprolol, atenolol or metoprolol
Study: 11156042
Drug: PLA barrier
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA barrier in combination with DFDBA
Study: 9196381
Drug: L‐NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (3 mg/kg administered i.v. over 5 minutes)
Study: 29605319
Drug: 5-hydroxy-l-tryptophan (5-HTP)
Normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxy-l-tryptophan (5-HTP) 1 mg/kg
Study: 29605319
Drug: 5-hydroxy-l-tryptophan (5-HTP)
Normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxy-l-tryptophan (5-HTP) with negative DCAD diet
Study: 23098865
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg daily for 10 days
Study: 19443519
Drug: Ismigen (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ismigen (one capsule daily for the first 10 days of three consecutive months)
Study: 11966949
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg acutely, 12.5 mg daily for 7 days)
Study: 11966949
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg acutely, 80 mg daily for 7 days)
Study: 9846467
Drug: Self-administered ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered ciprofloxacin eardrops at home, n = 40 (48 ears)
Study: 2598571
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered alone (750 mg) as control treatment
Study: 2598571
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered 5 to 10 minutes after antacid (30 ml)
Study: 2598571
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered 2 hours after antacid (30 ml)
Study: 2598571
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered 4 hours after antacid (30 ml)
Study: 2598571
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered 6 hours after antacid (30 ml)
Study: 2598571
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered 2 hours after ranitidine (200 mg)
Study: 241181
Drug: Intermittent dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosage schedules of antipsychotic preparations with reduced antiparkinsonic agents
Study: 241181
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of chlorpromazine
Study: 28804124
Drug: Imatinib (IM)
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib (IM) at 400 mg/day
Study: 26441006
Drug: risperidone or
Normalized name: risperidone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone or flupenthixol long acting injection
Study: 21267072
Drug: Pyronaridine-artesunate (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine-artesunate (target dose 7.2:2.4 mg/kg to 13.8:4.6 mg/kg) once daily for three days
Study: 21267072
Drug: Chloroquine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (standard dose) once daily for three days
Study: 16223754
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (100 microl per dose)
Study: 15349002
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg buprenorphine sublingual
Study: 15349002
Drug: i.v./sublingual placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v./sublingual placebo
Study: 15349002
Drug: escalating i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalating i.v. buprenorphine (2, 4, 8, 12, and 16 mg)
Study: 11185667
Drug: i.v. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration
Study: 15349002
Drug: sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual administration
Study: 15349002
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg i.v. dose
Study: 11739135
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 microg twice a day
Study: 11739135
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of detection and treatment
Study: 3617996
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy with MTX and 5-FU (therapy arm A)
Study: 3617996
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (therapy arm B)
Study: 26997579
Drug: APF530 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF530 500 mg subcutaneously
Study: 22427029
Drug: Topical spray
Normalized name: Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spray with 10% lignocaine and xylometazoline drops
Study: 18407376
Drug: Standardized volume/weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized volume/weight-based dose reformulation
Study: 12529662
Drug: Hypoplasia period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoplasia period after induction therapy
Study: 10462235
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis (aP) vaccine
Study: 8690109
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GNRH‐a) therapy
Study: 1750588
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg dihydrocodeine